ATE442354T1 - Pyrrolidinderivate als oxytocin antagonisten - Google Patents

Pyrrolidinderivate als oxytocin antagonisten

Info

Publication number
ATE442354T1
ATE442354T1 AT03762692T AT03762692T ATE442354T1 AT E442354 T1 ATE442354 T1 AT E442354T1 AT 03762692 T AT03762692 T AT 03762692T AT 03762692 T AT03762692 T AT 03762692T AT E442354 T1 ATE442354 T1 AT E442354T1
Authority
AT
Austria
Prior art keywords
sub
pyrrolidine derivatives
oxytocin antagonists
sup
forms
Prior art date
Application number
AT03762692T
Other languages
English (en)
Inventor
Catherine Jorand-Lebrun
Jerome Dorbais
Anna Quattropani
Matthias Schwarz
Delphine Valognes
Original Assignee
Merck Serono Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Serono Sa filed Critical Merck Serono Sa
Application granted granted Critical
Publication of ATE442354T1 publication Critical patent/ATE442354T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06Antiabortive agents; Labour repressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/10Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D249/00Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/081,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AT03762692T 2002-07-05 2003-07-04 Pyrrolidinderivate als oxytocin antagonisten ATE442354T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP02100784 2002-07-05
PCT/EP2003/050286 WO2004005249A1 (en) 2002-07-05 2003-07-04 Pyrrolidine derivatives as oxytocin antagonists

Publications (1)

Publication Number Publication Date
ATE442354T1 true ATE442354T1 (de) 2009-09-15

Family

ID=30011225

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03762692T ATE442354T1 (de) 2002-07-05 2003-07-04 Pyrrolidinderivate als oxytocin antagonisten

Country Status (19)

Country Link
US (1) US7115754B2 (de)
EP (1) EP1532109B1 (de)
JP (1) JP4851085B2 (de)
CN (1) CN1330633C (de)
AT (1) ATE442354T1 (de)
BR (1) BR0312586A (de)
CA (1) CA2487532C (de)
DE (1) DE60329189D1 (de)
EA (1) EA008479B1 (de)
ES (1) ES2330841T3 (de)
HR (1) HRP20041208A2 (de)
IL (1) IL166103A0 (de)
MX (1) MXPA05000326A (de)
NO (1) NO20050612L (de)
PL (1) PL374666A1 (de)
RS (1) RS115804A (de)
UA (1) UA78058C2 (de)
WO (1) WO2004005249A1 (de)
ZA (1) ZA200409820B (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20040030678A (ko) * 2001-06-18 2004-04-09 어플라이드 리서치 시스템스 에이알에스 홀딩 엔.브이. 피롤리딘 옥사디아졸 및 티아디아졸 유도체
RU2380110C1 (ru) * 2008-06-16 2010-01-27 Институт прикладной механики Уральского отделения Российской Академии Наук Способ стимуляции родов по н.а. михайловой
US10722645B2 (en) 2011-12-21 2020-07-28 Deka Products Limited Partnership Syringe pump, and related method and system
EP2845850A1 (de) * 2013-09-10 2015-03-11 ObsEva S.A. Pyrrolidinderivate als Oxytocin/Vasopressin-V1a-Rezeptorantagonisten
EP2886107A1 (de) 2013-12-17 2015-06-24 ObsEva S.A. Orale Formulierungen von Pyrrolydinderivaten
EP3753921A1 (de) * 2014-07-02 2020-12-23 ObsEva S.A. Kristallines (3z,5s)-5-(hydroxymethyl)-1-[(2'-methyl-1,1'-biphenyl-4-yl)carbonyl]pyrrolidin-3-on-o-methyloxim und verfahren zur verwendung davon
EP3037101B1 (de) * 2014-12-22 2019-03-06 Ferring B.V. Oxytocinrezeptorantagonistentherapie in der Lutealphase für Implantation und Schwangerschaft bei mit Technologien zur unterstützten Fortpflanzung behandelten Frauen
CA3009576A1 (en) 2016-01-04 2017-07-13 Merck Serono S.A. L-valinate of hydroxypropylthiazolidine carboxamide derivative and salt form, crystal polymorph thereof
UA127283C2 (uk) 2016-07-21 2023-07-12 Обсева С.А. Спосіб застосування антагоніста окситоцину для сприяння імплантації ембріона і запобігання викидню
US20220323410A1 (en) 2019-09-03 2022-10-13 ObsEva S.A. Oxytocin antagonist dosing regimens for promoting embryo implantation and preventing miscarriage
WO2021160597A1 (en) 2020-02-10 2021-08-19 ObsEva S.A. Biomarkers for oxytocin receptor antagonist therapy
TW202435864A (zh) 2023-02-09 2024-09-16 大陸商上海葆正醫藥科技有限公司 亞胺化合物及其製備方法和應用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6329418B1 (en) * 1998-04-14 2001-12-11 The Procter & Gamble Company Substituted pyrrolidine hydroxamate metalloprotease inhibitors
DK1268419T3 (da) * 2000-03-27 2006-10-02 Applied Research Systems Farmaceutisk aktive pyrrolidinderivater som BAX-inhibitorer

Also Published As

Publication number Publication date
JP4851085B2 (ja) 2012-01-11
CN1678576A (zh) 2005-10-05
ES2330841T3 (es) 2009-12-16
PL374666A1 (en) 2005-10-31
IL166103A0 (en) 2006-01-15
NO20050612L (no) 2005-02-03
CN1330633C (zh) 2007-08-08
EP1532109B1 (de) 2009-09-09
ZA200409820B (en) 2006-07-26
CA2487532A1 (en) 2004-01-15
CA2487532C (en) 2011-03-08
RS115804A (sr) 2007-02-05
UA78058C2 (en) 2007-02-15
US7115754B2 (en) 2006-10-03
MXPA05000326A (es) 2005-03-31
HRP20041208A2 (en) 2005-06-30
WO2004005249A1 (en) 2004-01-15
EA200500133A1 (ru) 2005-08-25
JP2005533828A (ja) 2005-11-10
DE60329189D1 (de) 2009-10-22
HK1076107A1 (en) 2006-01-06
BR0312586A (pt) 2005-04-12
US20060004020A1 (en) 2006-01-05
AU2003254498A1 (en) 2004-01-23
EP1532109A1 (de) 2005-05-25
EA008479B1 (ru) 2007-06-29

Similar Documents

Publication Publication Date Title
EA200301216A1 (ru) Замещенные хинуклидинами мультициклические гетероарилы для лечения заболевания
ATE368656T1 (de) Piperidinderivate zur verwendung bei der behandlung von durch chemokins vermittelten leiden
ATE357434T1 (de) Disubstituierte thiazolylcarboxanilide und ihre verwendung als mikrobizide
NO20072605L (no) Nytt antranilinsyrederivat eller et salt derav
DE69912581D1 (de) Biarylessigsäure-derivate und ihre verwendung als cox-2 inhibitoren
ATE440087T1 (de) 2,4-diaminopyrimidinderivate, die sich als inhibitoren von pkc-theta eignen
NO20062950L (no) 5,7-diaminopyrazolo `43-Dlpyrimidiner med PDE-5 inhiberende aktivitet
NO20053794L (no) N-(1-benzyl-2-oxo-2-(1-piperazinyl) etyl)-1-piperidinkarboksamid-derivater og relaterte forbindelsers bruk som CGRP-antagonister for behandling av hodepine.
EA200500342A1 (ru) Гетероциклические замещённые пиперазины для лечения шизофрении
PE20021002A1 (es) Compuestos heterociclicos condensados
AR041298A1 (es) Derivados de pirrolidona como inhibidores de maob
NO20050199L (no) Azadisyklo-oktan og nonanderivater med DDP-IV-inhiberende aktivitet
ATE540928T1 (de) Isochinolinverbindungen und ihre medizinische verwendung
NO20050134L (no) Difenylazetidioner substituert med syregrupper, fremgangsmate for fremstilling av disse, medikamenter inneholdende disse forbindelser og deres anvendelse
NO20055977L (no) Nye benzimidazolderivater
NO20053762L (no) Kondensert furanforbindelse.
ATE442354T1 (de) Pyrrolidinderivate als oxytocin antagonisten
NO20062021L (no) Omleirede pentanoler, fremgangsmpte for fremstilling av dette, og deres anvendelse som antiflogistika
DE60335404D1 (de) Verwendung von 4-aminochinolin-verbindungen zur behandlung entzündlicher erkrankungen des auges
NO20040388L (no) Fremgangsmåte for fremstilling av beraprost og salter derav, samt forbindelser som er mellomprodukter i fremgangsmåten
CO5680420A2 (es) Compuestos de 6-amino-1h-indazol y 4-aminobenzenofurano como inhibidores de la fosfodiesterasa 4
DE50304891D1 (de) N-aryl-4,5-diaminopyrazole und diese verbindungen enthaltende färbemittel
NO20060718L (no) Substituerte tiofoner og deres anvendelse
NO20050270L (no) Nye forbindelser, deres anvendelse og fremstilling
NO20030509L (no) Nye N-(2-fenyl-3-aminopropyl)naftamider

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties